GREAT NECK, N.Y.--(BUSINESS WIRE)-- Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company’s monoclonal antibody for colorectal and pancreatic cancer. Invented and developed by Neogenix Oncology, this antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in vitro and animal studies and may have both therapeutic and diagnostic applications. This patent covers the third distinct monoclonal antibody held by Neogenix.
“This patent is another major step for Neogenix to move forward in our research for the diagnosis and treatment of a broad range of cancers. We believe that 16C3 has the potential to become an important addition to Neogenix’s new diagnostic and therapeutic tools in the fight against colorectal and pancreatic cancer. The antibody may have activity in other tumors as well, which the company will explore as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody,” said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.
The USPTO has previously granted patents for Neogenix Oncology’s lead monoclonal antibody NPC-1C (ensituximab) as well as its monoclonal antibody, 31.1.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic test for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of ensituximab (NPC-1C antibody) in patients with metastatic pancreatic and colorectal cancer. For more information on Neogenix Oncology, please visit www.neogenix.com.
Forward Looking Statements
Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
RMT PR Management
RoseMarie Terenzio, 212-414-1909
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology